April 2026 Gilead Sciences completed the acquisition of Arcellx, strengthening its regenerative medicine and advanced cell and acellular therapy portfolio while accelerating the development and commercialization of anitocabtagene autoleucel (anito-cel).
March 2025 EVAST Bio developed a small extracellular vesicle (sEV)-based acellular therapy for knee osteoarthritis, advancing regenerative treatment options that promote cartilage repair and reduce inflammation without using living cells.
February 2025 Humacyte initiated the commercial launch of Symvess™, its FDA-approved acellular tissue-engineered vessel (ATEV), marking a significant commercial milestone in regenerative acellular therapies.